Summary
CMIIU Chart
Columbus Circle Capital Corp II Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DS Danny Salinas Cantor Fitzgerald LP | 19,518 | $213,722.1 | $213,722.1 | - | - |
| DB David Barlow Glazer Capital LLC | 1,444 | $14,000 | $14,000 | - | - |
| CW CaSaundra Wu Westchester Capital Management LLC | 150,000 | $1.49M | $1.49M | - | - |
| BO Brian Oliveira Clear Street Group Inc. | 66,903 | $693,848.01 | $732,587.85 | $38,739.84 | 5.58% |
Columbus Circle Capital Corp II (CMIIU) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Columbus Circle Capital Corp II Profile
| Trading Companies & Distributors Industry | Industrials Sector | Kevin Shannon CEO | NASDAQ (NGS) Exchange | G2296M111 CUSIP |
| US Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CM Life Sciences II Inc. operates as a blank check company, having no significant operations of its own. Established in 2020, this corporation is situated in New York, New York, and its primary objective is to identify potential candidates for business combination opportunities within the life sciences domain. The company intends to pursue various strategies including mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or any similar business combinations. By focusing on the life sciences sector, CM Life Sciences II Inc. aims to contribute to advancements that may enhance health, wellness, and the overall quality of life.
Products and Services
- Mergers and Acquisitions
CM Life Sciences II Inc. actively seeks to engage in merging with or acquiring companies that operate within the life sciences sector. This approach enables the company to leverage existing expertise and resources, thereby fostering innovation and growth.
- Capital Stock Exchange
The company plans to facilitate capital stock exchanges that allow for the transition of ownership and control in target companies, thereby creating synergistic opportunities geared towards enhancing their operational capabilities.
- Asset Acquisition
Through targeted asset acquisitions, CM Life Sciences II Inc. can secure vital resources and technologies that can propel forward initiatives in the life sciences field. This strategy is crucial for strengthening the company's portfolio.
- Stock Purchases
Conducting stock purchases enables CM Life Sciences II Inc. to acquire significant stakes in promising life sciences firms, allowing the company to influence decision-making and strategic direction within these entities.
- Reorganization
Reorganization efforts may be implemented to streamline operations within acquired businesses, enhancing efficiency and aligning objectives that contribute to overall mission success in the life sciences sphere.
- Business Combinations
Ultimately, CM Life Sciences II Inc. aims to achieve successful business combinations that can integrate diverse strengths from multiple organizations, driving collective advancement in the life sciences sector.
Contact Information
